MindImmune Therapeutics

Funding and NIH signals

• SEC Form D raise Raised $15.22M (Form D filed Dec 5, 2025; amended Mar 5, 2026). SEC Form D 0001792522-25-000002 (Dec 5, 2025)
  Evidence (1 event)

  • Dec 5, 2025 · SEC Form D 0001792522-25-000002
    Name of Issuer: MindImmune Therapeutics, Inc.; CIK: 1792522; Address: Kingston, RI; Submission type: D; Filing date: 2025-12-05; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-24; Types of Securities Offered: Equity, Security to be acquired; Business combination transaction: false; Total Offering Amount: 12000000; Total Amount Sold: 10203858; Federal exemptions: 06b || Name of Issuer: MindImmune Therapeutics, Inc.; CIK: 1792522; Address: Kingston, RI; Submission type: D/A; Filing date: 2026-03-05; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-24; Types of Securities Offered: Equity, Security to be acquired; Business combination transaction: false; Total Offering Amount: 17014485; Total Amount Sold: 15218343; Federal exemptions: 06b
• NIH award NIH awarded $496K (SBIR Phase I 1R43AG102103-01, new, notice Sep 17, 2026). NIH RePORTER 1R43AG102103-01 (Sep 17, 2026)
  Evidence (1 event)

  • Sep 17, 2026 · NIH RePORTER 1R43AG102103-01
    Organization: MINDIMMUNE THERAPEUTICS, INC.; City/State: KINGSTON, RI; Project number: 1R43AG102103-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 496415; Administering IC: National Institute on Aging; Project title: Targeting CD11c immune cells to alleviate cerebral amyloid angiopathy and amyloid-related imaging abnormality in patients with Alzheimer's disease; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals